Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Traws Pharma (TRAW) Operating Expenses (2016 - 2025)

Traws Pharma (TRAW) has disclosed Operating Expenses for 14 consecutive years, with $7.4 million as the latest value for Q4 2025.

  • For Q4 2025, Operating Expenses rose 38.13% year-over-year to $7.4 million; the TTM value through Dec 2025 reached $20.7 million, down 85.51%, while the annual FY2025 figure was $20.7 million, 85.51% down from the prior year.
  • Operating Expenses hit $7.4 million in Q4 2025 for Traws Pharma, up from $4.1 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $123.4 million in Q2 2024 and bottomed at $3.8 million in Q4 2021.
  • Average Operating Expenses over 5 years is $11.0 million, with a median of $4.9 million recorded in 2021.
  • Year-over-year, Operating Expenses soared 2544.2% in 2024 and then crashed 96.77% in 2025.
  • Traws Pharma's Operating Expenses stood at $3.8 million in 2021, then surged by 51.61% to $5.8 million in 2022, then dropped by 21.97% to $4.5 million in 2023, then increased by 18.06% to $5.3 million in 2024, then surged by 38.13% to $7.4 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $7.4 million, $4.1 million, and $4.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.